Inmune Bio
Inmune Bio
INMB
NASDAQ
8.45
USD
5.10%
About
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform.
The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro).
The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 191.7K |
| Three Month Average Volume | 3.8M |
| High Low | |
| Fifty-Two Week High | 14.74 USD |
| Fifty-Two Week Low | 6.41 USD |
| Fifty-Two Week High Date | 14 Feb 2024 |
| Fifty-Two Week Low Date | 21 Aug 2024 |
| Price and Volume | |
| Current Price | 6.62 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -23.30% |
| Thirteen Week Relative Price Change | -34.55% |
| Twenty-Six Week Relative Price Change | -51.41% |
| Fifty-Two Week Relative Price Change | -34.78% |
| Year-to-Date Relative Price Change | -50.35% |
| Price Change | |
| One Day Price Change | -3.50% |
| Thirteen Week Price Change | -29.95% |
| Twenty-Six Week Price Change | -46.57% |
| Five Day Price Change | -4.75% |
| Fifty-Two Week Price Change | -18.27% |
| Year-to-Date Price Change | -41.21% |
| Month-to-Date Price Change | -22.93% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.12464 USD |
| Book Value Per Share (Most Recent Quarter) | 1.88159 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.20468 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.0436 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.06035 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00862 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00463 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.66889 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.05842 USD |
| Normalized (Last Fiscal Year) | -1.66889 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.66889 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.05842 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.66889 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.05842 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.99702 USD |
| Cash Per Share (Most Recent Quarter) | 1.57657 USD |
| Cash Flow Per Share (Last Fiscal Year) | -99999.99 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.25549 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -12,831 |
| Cash Flow Revenue (Trailing Twelve Months) | -27,091 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -44,402.35% |
| Pretax Margin (Last Fiscal Year) | -19,360.00% |
| Pretax Margin (5 Year) | -14,901.03% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -19,187.74% |
| Operating Margin (Trailing Twelve Months) | -44,457.65% |
| Operating Margin (5 Year) | -14,540.96% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -19,360.00% |
| Net Profit Margin (Trailing Twelve Months) | -44,402.35% |
| Net Profit Margin (5 Year) | -14,901.03% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 4.58% |
| Tangible Book Value (5 Year) | 284.96% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -69.53% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 142.12% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -39.35% |
| EPS Change (Trailing Twelve Months) | -38.90% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 6 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -26,090,000 |
| Net Debt (Last Fiscal Year) | -25,927,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 844 |
| Price to Sales (Trailing Twelve Months) | 1.5K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 4 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -11,980,000 |
| Free Cash Flow (Trailing Twelve Months) | -23,027,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -13 |
| Net Interest Coverage (Trailing Twelve Months) | -23 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 26 |
| Total Debt to Equity (Most Recent Quarter) | 13 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -43.24% |
| Return on Assets (Trailing Twelve Months) | -61.78% |
| Return on Assets (5 Year) | -37.82% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -61.09% |
| Return on Equity (Trailing Twelve Months) | -86.04% |
| Return on Equity (5 Year) | -46.70% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -54.85% |
| Return on Investment (Trailing Twelve Months) | -80.24% |
| Return on Investment (5 Year) | -41.86% |